Captopril: An Update of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Use in Hypertension and Congestive Heart Failure

Drugs

Volumn 36, Issue 5, 1988, Pages 540-600

  Brogden, Rex N ^a   Todd, Peter A ^a   Sorkin, Eugene M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE; DIURETIC AGENT; ENALAPRIL; HYDRALAZINE; METHYLDOPA; NISOLDIPINE; PRAZOSIN; PROPRANOLOL;

AGE; CONTROLLED STUDY; DRUG TOLERANCE; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SCLERODERMA;

CAPTOPRIL; HEART FAILURE, CONGESTIVE; HUMAN; HYPERTENSION;

EID: 0023698867     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-198836050-00003     Document Type: Article

References (471)

1. The interaction of renin-angiotensin-aldosterone system and renal depressor system
2. Indomethacin (ind) inhibits an enhanced renin release following captopril, SQ 14225, administration
3. Comparison of captopril (SQ 14225) with hydrochlorothiazide in the treatment of essential hypertension
4. Effect of naloxone on the actions of captopril
5. Clinical experience with captopril in the treatment of severe and resistant hypertension
6. Comparison of the hormonal and renal effects of captopril in severe essential and renovascular hypertension
7. Captopril-induced oesophagitis
8. Hypotensive mechanism of captopril
9. The role of renal hemodynamics in the antihypertensive effect of captopril
10. Captopril and atenolol combined with hydrochlorothiazide in essential hypertension
11. Long term effects of captopril and atenolol in essential hypertension
12. Captopril as first step therapy in elderly hypertensive diabetic patients
13. Tratamiento de la hipertensión arterial esencial del anciano con captopril e hidrochlorotiazida a bajas dosis. Estudio a largo plazo
14. Agranulocytose au captopril
15. Captopril in hypertension with renal artery stenosis and in intractable hypertension: acute and chronic changes in circulating concentrations of renin, angiotensin I and II and aldosterone, and in body composition
16. Captopril treatment: inter-dose variations in renin, angiotensins I and II, aldosterone and blood pressure
17. Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natriuresis
18. Hormonal and metabolic effects of angiotensin converting enzyme inhibitors: possible differences between enalapril and captopril
19. Captopril overdose resulting in hypotension
20. Long-term hemodynamic and clinical efficacy of captopril therapy in ambulatory management of severe chronic congestive heart failure
21. Vasodilator therapy of severe congestive heart failure: the special importance of angiotensin-converting enzyme inhibition with captopril
22. A study of the use of captopril in elderly hypertensive patients
23. Coronary hemodynamic effects of angiotensin inhibition in congestive heart failure
24. Quantitative determination of captopril in blood and captopril and its disulfide metabolites in plasma by gas chromatography
25. Vasodilatation with captopril and prazosin in chronic heart failure: double blind study at rest and on exercise
26. Clinical importance of the renin-angiotensin system in chronic heart failure: double blind comparison of captopril and prazosin
27. Use of captopril as early therapy for renal scleroderma: a prospective study
28. Naloxone does not modify the antihypertensive effect of captopril in essential hypertensive patients
29. Influence of ACE inhibition on pulmonary haemodynamics and function in patients in whom beta-blockers are contraindicated
30. Double comparative trial of captopril versus methyldopa in mild and moderate hypertension
31. Treatment of neonatal hypertension with captopril
32. Long term therapy by captopril in children with renal hypertension
33. Beneficial effects of captopril in left ventricular failure in patients with myocardial infarction
34. Captopril administration in pregnancy impairs fetal angiotensin converting enzyme activity and neonatal adaptation
35. Converting enzyme inhibition with an orally active compound in hypertensive man
36. Cerebral blood flow in hypertensive patients with cerebrovascular disease: technique for measurement and effect of captopril
37. Antihypertensive treatment using calcium antagonists in combination with captopril rather than diuretics
38. Clinical use of an orally acting converting enzyme inhibitor: captopril
39. Inhibition of angiotensin converting enzyme by 2-[N-[(s)-l-carboxy-3-phenylpropyl]-L-alanyl]-(lS, 3S, 5S)-2-azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498) diacid: comparison with captopril and enalaprilat
40. Captopril and domiciliary oxygen in chronic airflow obstruction
41. Long term treatment with captopril in pediatric patients with severe hypertension and chronic renal failure
42. Circulating and tissue angiotensin systems
43. Combined haemodynamic effects of digoxin and captopril in patients with congestive heart failure
44. Does captopril cause renal damage in hypertensive patients?
45. A placebo-controlled trial of captopril in refractory chronic congestive heart failure
46. A cooperative multicenter study of captopril in congestive heart failure: hemodynamic effects and long term response
47. Clinical effects of low-dose captopril plus a thiazide diuretic on mild to moderate essential hypertension. A multicenter double-blind comparison with propranolol
48. Reactive hyperreninemia to angiotensin blockade identified renovascular hypertension
49. Long term efficacy of captopril in renovascular and essential hypertension
50. Clinical experience with captopril in moderate to severe hypertension
51. Captopril for the treatment of patients with hypertension and peripheral vascular disease
52. Guillain-Barré neuropathy during treatment with captopril
53. Postmarketing surveilance of captopril for hypertension: a preliminary report
54. Captopril in hypertension after renal transplantation
55. Haemodynamic and myocardial metabolic effects of captopril in chronic heart failure
56. In-vitro response of plasma angiotensin converting enzyme to precursors and active forms of converting enzyme inhibitors
57. A comparative study of captopril and enalapril in patients with severe hypertension
58. Captopril in heart failure: a double blind controlled trial
59. The effects of captopril on serum digoxin and urinary urea and digoxin clearances in patients with congestive heart failure
60. Interaction of angiotensin-converting enzyme inhibitors with the function of the sympathetic nervous system
61. The effect of captopril on postural hemodynamics and autonomic responses in chronic heart failure
62. Haemodynamic responses to specific renin-angiotensin inhibitors in hypertension and congestive heart failure: a review
63. Captopril pharmacokinetics in chronic heart failure: correlation with acute hemodynamic and hormonal response
64. Captopril pharmacokinetics and the acute hemodynamic and hormonal response in patients with severe congestive heart failure
65. Sympathetic responsiveness and plasma norepinephrine during therapy of chronic congestive heart failure with captopril
66. Combined vasodilator therapy for chronic congestive heart failure
67. Captopril kinetics in chronic congestive heart failure
68. Determination of captopril in human blood and urine by GLC-selected ion monitoring mass spectrometry after oral coadministration with its isotopomer
69. Identification and determination of the S-methyl metabolite of captopril in human plasma by selected-ion monitoring gas chromatography-mass spectrometry
70. Effects of enalapril on mortality in severe congestive heart failure
71. Captopril-associated neutropenia
72. Treating hypertension in non-insulin-dependent diabetes: a comparison of atenolol, nifedipine and captopril combined with bendrofluazide
73. Captopril compared with nifedipine in the treatment of heart failure: a randomized study
74. Low dose captopril therapy in mild and moderate hypertension
75. Converting enzyme inhibition vs diuretic therapy as first therapeutic approach to the elderly hypertensive patient
76. Captopril and oxprenolol in a fixed combination with thiazide diuretics: comparison of their antihypertensive efficacy and metabolic effects
77. Low doses of captopril in association with once or twice daily hydrochlorothiazide in essential hypertension: long term efficacy and safety
78. Differing dosages of caplopril and hydrochlorothiazide in the treatment of hypertension: long term effects on metabolic values and intracellular electrolytes
79. Eye pain with nifedipine and disturbance of taste with captopril: a mutually controlled study showing a method of postmarketing surveillance
80. Cough associated with captopril and enalapril
81. Effects of captopril on abnormalities on the peripheral circulation and respiratory function in patients with severe heart failure
82. Haemodynamic and neurohumoral response to exercise in patients with congestive heart failure treated with captopril
83. Acute regional circulatory and renal hemodynamic effects of converting-enzyme inhibition in patients with congestive heart failure
84. Pharmacokinetics of captopril in elderly healthy male volunteers
85. Sexual symptoms in hypertensive patients
86. The effects of antihypertensive therapy on the quality of life
87. Effects of converting enzyme inhibitor on hepatic blood flow in man
88. Captopril and kallikrein
89. Efficacy of captopril in hypertensive diabetic patients
90. Captopril in the treatment of hypertension in type I and type II diabetic patients
91. Captopril administration to the pregnant guinea pig inhibits fetal angiotensin converting enzyme activity
92. Once daily therapy with angiotensin converting enzyme inhibitors in mild hypertension: a comparison of captopril and enalapril
93. Labetolol and captopril combined with chlorthalidone in the treatment of mild to moderate essential hypertension
94. Prolonged treatment of essential hypertension and renal function: comparison of captopril and betablockers considering microproteinuria values
95. The antihypertensive efficacy of captopril given once, twice, and three times daily
96. Captopril in human blood and breast milk
97. Angiotensin converting enzyme inhibition
98. Survival in patients with heart failure: focus on captopril
99. Optimal dose of captopril in hypertension. Correspondence
100. Effect of converting enzyme inhibitors in hypertensive patients with non-insulin dependent diabetes mellitus
101. II) and bradykinin (BK) after incremental doses of captopril (SQ 14,225)
102. Differential effects of diuresis and beta-adrenoceptor blockade during angiotensin-converting enzyme inhibition in patients with severe hypertension
103. The disposition and metabolism of captopril
104. Combined gas chromatographic-mass spectrometric procedure for the measurement of captopril and sulfur-conjugated metabolites of captopril in plasma and wine
105. Inhibition of angiotensin converting enzyme by metabolites of captopril
106. The pharmacokinetics of captopril and captopril disulfide conjugates in uraemic patients on maintenance dialysis: comparison with patients with normal renal function
107. Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases
108. Elimination kinetics of captopril in patients with renal failure
109. Captopril kinetics
110. The effect of captopril on renal hemodynamics in hypertensive patients
111. Traitement à long terme par le captopril de l’hypertension artérielle associée à une insuffisance rénale
112. Circulating versus local renin-angiotensin system in cardiovascular homeostasis
113. Sustained effectiveness of converting-enzyme inhibition in patients with severe congestive heart failure
114. Renal response to captopril in severe heart failure: role of furosemide in natriuresis and reversal of hyponatremia
115. Captopril: 4 years of post marketing surveillance of all patients in New Zealand
116. Angiotensin-converting enzyme inhibitors: past, present, and bright future
117. Fatal bone-marrow suppression associated with captopril
118. Control of essential hypertension with captopril, an angiotensin converting enzyme inhibitor
119. Comparison of captopril and atenolol in the treatment of hypertension in patients with diabetes mellitus
120. Effects of captopril on hepatic venous pressure and blood flow in patients with liver cirrhosis
121. Effect of captopril at two different dosage regimens in hypertensive non-insulin dependent patients
122. Captopril in essential hypertension
123. Effects of captopril on blood pressure, metabolic control, plasma lipids, and proteinuria in elderly hypertensive diabetics
124. Response of the systemic and pulmonary circulation to converting-enzyme inhibition (captopril) at rest and during exercise in hypertensive patients
125. An orally active angiotensin I-converting enzyme inhibitor for therapy of hypertension
126. Angiotensin-converting enzyme inhibition: a new medical therapy for hypertension?
127. Regional circulatory response to converting-enzyme inhibition in congestive heart failure
128. Redistribution of regional blood flow following angiotensin-converting enzyme inhibition
129. A specific orally active inhibitor of angiotensin-converting enzyme in man
130. Comparison of the effects of captopril, diuretic and their combination in low- and normal-renin essential hypertension
131. Captopril in the treatment of mild essential hypertension
132. Effects of intradermal bradykinin after inhibition of angiotensin converting enzyme
133. Captopril and insulin sensitivity
134. Clinical and haemodynamic effects of nisoldipine and captopril in heart failure: a double blind comparative study of the short and long term effects (translation)
135. Captopril during pregnancy
136. Comparison of captopril and hydralazine in refractory heart failure: an acute haemodynamic study
137. Hypotensive effect of once daily administration of captopril
138. Long-term efficacy of captopril in congestive heart failure
139. Captopril scintigraphy in arterial hypertension: evaluation of scintigraphic results in relation to blood pressure and renin responses
140. Sustained antihypertensive effect of captopril combined with diuretics and beta adrenergic blocking drugs in patients with resistant hypertension
141. Long term control of congestive heart failure with captopril
142. Age and antihypertensive drugs (hydrochlorothiazide, bendroflumethiazide, nadolol and captopril)
143. Effect of captopril and hydrochlorothiazide on the response to pressor agents in hypertensives
144. Hemodynamic and endocrine changes associated with captopril in diuretic-resistant hypertensive patients
145. Increased cough reflex associated with angiotensin converting enzyme inhibitor cough
146. Effect of vasodilators on survival in chronic congestive heart failure
147. Gas chromatography/selected ion monitoring mass spectrometric determination of captopril in human blood
148. Captopril and transplant renal artery stenosis in children
149. Captopril in the treatment of hypertension in type I and type II diabetic patients
150. A comparison of once-daily antihypertensive therapy with captopril and enalapril
151. Fatal pancytopenia associated with the use of captopril
152. Acute oral captopril inhibits angiotensin converting enzyme activity in human cerebrospinal fluid
153. Captopril and hydrochlorothiazide in elderly patients with mild-moderate hypertension
154. Influence of chronic renal failure on captopril pharmacokinetics and clinical and biological effects in hypertensive patients
155. Long-term effects of captopril on renal function in hypertensive patients
156. Increased plasma arginine vasopressin levels in patients with congestive heart failure
157. Efecto de un inhibidor de la enzima conversiva de la angiotensina I (captopril) en diabéticos hipertensos sin nefropatia
158. Minoxidil and captopril in severe hypertension
159. Long term antihypertensive therapy with captopril
160. Persistent captopril-associated taste alternation
161. Calcium channel blockade with nifedipine and angiotensin converting enzyme inhibition with captopril in the therapy of patients with severe primary hypertension
162. Captopril versus acebutolol in the treatment of diabetic patients with moderate essential hypertension
163. Long term experience with captopril in severe hypertension
164. Determination of captopril and its mixed disulphides in plasma and urine by high-performance liquid chromatography
165. Distribution in rats of an inhibitor of angiotensin-converting enzyme, SQ 14,225, as studied by whole-body autoradiography and liquid scintillation counting
166. Captopril: a preliminary review of its pharmacological properties and therapeutic efficacy
167. Haemolytic anaemia: possible complication of captopril therapy
168. Captopril in hypertension after renal transplantation
169. Comparative analysis of the hemodynamic actions of captopril and sodium nitroprusside in severe chronic congestive heart failure
170. Angiotensin converting enzyme inhibitors and quality of life: The European Trial
171. Worsening of anaemia induced by long-term use of captopril in hemodialysis patients
172. Captopril (SQ 14,225) clearance during haemodialysis treatment
173. Low dose administration of captopril in severely hypertensive children
174. Factors related to first dose hypotensive effect of captopril: prediction and treatment
175. Synergistic effect of captopril with hydrochlorothiazide for the treatment of low-renin hypertensive black patients
176. Renal haemodynamics in essential and renovascular hypertension: influence of captopril
177. Effect of captopril on kidney function in insulin-dependent diabetic patients with nephropathy
178. Membranous glomerulopathy in a patient on captopril
179. Effects of captopril on prostaglandin and natriuresis in patients with essential hypertension
180. Comparison of antihypertensive effects of captopril and propranolol in essential hypertension
181. Long term treatment of hypertension in a preterm infant and in older children
182. Haemodynamic and hormonal effects of captopril in primary pulmonary hypertension
183. Attenuation of pressor responses to norepinephrine and pitressin and potentiation of pressor response to angiotensin II by captopril in human subjects
184. Captopril attenuates pressor responses to norepinephrine and vasopressin through depletion of endogenous angiotensin II
185. Comparative effect of captopril and nifedipine in normotensive patients with incipient diabetic nephropathy
186. Reversible Panmyelopathie nach Captopril-Medikation
187. Captopril-associated transient aplastic anemia
188. Spectrofluorometric determination of captopril plus captopril disulfide metabolites in plasma
189. Determination of total captopril in human plasma by gas chromatography-mass spectrometry with selected-ion monitoring after reduction of disulfides
190. Treatment of hypertension with captopril: preservation of regional blood flow and reduced platelet aggregation
191. High-performance liquid Chromatographic analysis of captopril in plasma
192. Pharmacokinetic properties of captopril after acute and chronic administration to hypertensive subjects
193. Simultaneous determination of captopril and S-benzoyl captopril in human blood by capillary gas chromatography-mass selective detection
194. Captopril in hypertension: seven years later
195. Captopril in the treatment of the elderly hypertensive patient
196. Review of clinical studies of hypertensive patients treated with captopril
197. Captopril-induced angioedema
198. Dilation of forearm blood vessels after angiotensin-converting-enzyme inhibition by captopril in hypertensive patients
199. Acute and chronic effect of captopril in hypertensive patients
200. Comparison of the hormonal effects of captopril (SQ 14225) and hydrochlorothiazide in the treatment of essential hypertension
201. Long-term effects of captopril (SQ 14225) on blood pressure and hormone levels in essential hypertension
202. Long term experience of captopril in the treatment of primary (essential) hypertension
203. Captopril lowers urinary kallikrein in hypertensive patients
204. Different effects of two angiotensin converting enzyme inhibitors in primary hypertension: a comparison of captopril and enalapril
205. Captopril in pulmonary hypertension
206. Captopril for geriatric hypertensives
207. Determination of captopril in blood and urine by high-performance liquid chromatography
208. Comparative study of once-daily administration of captopril 50mg, hydrochlorothiazide 25mg and their combination in mild to moderate hypertension
209. Therapie der chronischen Herzinsuffizienz (NYHA III und IV) mit Captopril-Akut- und Langzeitergebrisse
210. Antihypertensive and renal effects of captopril in relation to renin activity and bradykinin-induced vasodilation
211. Successful low dose captopril rechallenge following drug-induced leucopenia
212. Captopril and proteinuria in diabetes mellitus
213. Captopril in mild to moderate heart failure over 18 months: effects on morbidity and mortality
214. The contribution of sympathetic tone and the renin-angiotensin system to severe chronic congestive heart failure: response to specific inhibitors (prazosin and captopril)
215. Enalapril vs captopril as step II and methyldopa as step III drugs in hypertension
216. Captopril
217. In vitro studies on the metabolic pathway of SQ 14225 (captopril) and mechanism of mixed disulfide formation
218. Effects of angiotensin-I converting enzyme inhibitor, SQ 14225, in normal men
219. Controlled trial of captopril in chronic heart failure: a rest and exercise hemodynamic study
220. Disposition of captopril in normal subjects
221. Additive effects of moderate dietary salt reduction and captopril in hypertension
222. Effects of captopril on arterial and venous pressure, renal function, and humoral factors in severe chronic congestive heart failure
223. Effects of converting-enzyme inhibition on cardiorenal hemodynamics in patients with chronic congestive heart failure
224. Effects of captopril on cardiorenal hemodynamics in patients with severe chronic congestive heart failure
225. Regional and systemic metabolic effects of angiotensinconverting enzyme inhibition during exercise in patients with severe heart failure
226. Analysis of well-being and 24-hour blood pressure recording in a comparative study between indapamide and captopril
227. Captopril for refractory hypertension in patients with impaired renal function
228. Captopril once daily in patients with essential hypertension and hyperuricaemia
229. Effects of captopril, hydrochlorothiazide and their combination on timed urinary excretions of water and solutes
230. A discrepancy between the effects of a single oral dose of captopril on blood pressure, plasma renin activity, and serum angiotensin-converting enzyme levels
231. Captopril and hydrochlorothiazide in the fixed combination multicentre trial
232. Prognostic importance of serum sodium concentration and its modification by converting enzyme inhibition in patients with severe chronic heart failure
233. Captopril in primary pulmonary hypertension
234. Hemodynamic effects of captopril in patients with severe chronic heart failure
235. Systemic and regional hemodynamic effects of captopril and milrinone administered alone and concomitantly in patients with heart failure
236. Traitement de l’insuffisance cardiquechronique congestive sévère par le captopril
237. Determinants of acute and long-term response to converting enzyme inhibitors in congestive heart failure
238. Factors predicting acute and long-term response to captopril therapy in congestive heart failure
239. Acute and long term response to converting-enzyme inhibitor, captopril, in congestive heart failure
240. Hemodynamic and regional blood flow response to captopril in congestive heart failure
241. Proteinuria and abnormalities of the renal glomerulus in patients with hypertension
242. Captopril versus enalapril maleate: a comparison of antihypertensive and hormonal effects
243. Captopril in the treatment of hypertension associated with claudication
244. Increase in plasma aldosterone during prolonged captopril treatment
245. Captopril vs hydralazine in advanced congestive heart failure: comparison of one year survival
246. Left ventricular mass and function before and after antihypertensive treatment
247. Converting enzyme inhibition with captopril in patients with primary hyperaldosteronism
248. The humoral effects of captopril and furosemide in hypertensive patients
249. Captopril in essential hypertension; contrasting effects of adding hydrochlorothiazide or propranolol
250. Captopril: contrasting effects of adding hydrochlorothiazide, propranolol, or nifedipine
251. Relation between urinary kallikrein excretion and blood pressure response to a single oral dose of captopril
252. Converting enzyme inhibition and heart failure
253. Converting-enzyme inhibition and coronary blood flow
254. Once daily fixed combination captopril plus hydrochlorothiazide in the treatment of mild to moderate essential hypertension
255. Evaluation of the antihypertensive effect of once-a-day captopril by 24-hour ambulatory blood pressure monitoring
256. Dependence of enhanced exercise performance on increased skeletal muscle perfusion during long term captopril therapy in heart failure
257. Prazosin und captopril in der Kombinationstherapie de schwer einstellbaren Hypertonie
258. Ramipril and captopril in patients with heart failure: effects on haemodynamics and vasoconstrictor systems
259. Impairment of captopril bioavailability by concomitant food and antacid intake
260. Captopril, kallikrein and hypertension
261. Gynaecomastia associated with captopril. Correspondence
262. Captopril produces a short-term pulmonary vasodilatation in patients with pulmonary hypertension secondary to COPD
263. Hemodynamic and radionuclide effects of acute captopril therapy for heart failure
264. Lack of relationship between the short term hemodynamic effects of captopril and subsequent clinical responses
265. Hemodynamic responses to combined therapy with captopril and hydralazine in patients with severe heart failure
266. Determination of captopril and its disulphide in biological fluids
267. The effect of captopril on blood pressure and glucose tolerance in hypertensive non-insulin dependent diabetics
268. The use of captopril and captopril plus frusemide as antihypertensive agents in non-insulin dependent diabetes
269. The effects of angiotensin Iconverting enzyme inhibitors on arterial blood pressure and urinary sodium excretion: role of renal renin-angiotensin and kallikrein-kinin systems
270. The effect of repeated administration of captopril (CP) on its disposition in hypertensive patients
271. Disposition and cardiovascular-endocrine effects of an orally active angiotensin-converting enzyme inhibitor, SQ 14,225, in normal subjects
272. Captopril, enalapril, and blood glucose. Correspondence
273. Effects of chronic captopril therapy on blood pressure and left ventricular response to exercise in mild to moderate hypertension with and without cardiac hypertrophy
274. Captopril: pharmacology, metabolism, and disposition
275. Thin-layer radiochromatographic determination of captopril (SQ 14,225) and its disulfedimermetabolite in blood
276. Sequential changes in circulating levels of angiotensin I and II, renin and bradykinin after captopril
277. Attenuation of the antihypertensive effect of captopril by the opioid receptor antagonist naloxone
278. Effect of captopril on renal vascular tone in patients with essential hypertension
279. Effect of angiotensin converting enzyme inhibitor (captopril) on cerebral blood flow in hypertensive patients without a history of stroke
280. Efficacy and safety of captopril in the treatment of severe childhood hypertension: Report of the International Collaborative Study Group
281. Further studies of the hyperadrenergic state of treated hypertensives: effect of captopril
282. Effects of converting enzyme inhibition on split renal function in renovascular hypertension
283. Acute effects of captopril on cardiopulmonary hemodynamics and renin-angiotensin-aldosterone and bradykinin profile in hypertension
284. Contribution of prostaglandins to the antihypertensive action of captopril in essential hypertension
285. Kalemia during combined therapy with an angiotensin converting enzyme inhibitor and a potassium-sparing diuretic
286. Endocrine and cardiovascular influences of converting enzyme inhibition with SQ 14225 in hypertensive patients in the supine position and during head-up tilt before and after sodium depletion
287. Angiotensinconverting enzyme and the cough reflex
288. Responses to captopril and hydrochlorothiazide in black patients with hypertension
289. Antihypertensive efficacy and tolerability of captopril in the elderly: comparison with hydrochlorothiazide and placebo in a multicentre, double-blind study
290. A multicentre trial of low dose captopril administered twice daily in patients with essential hypertension unresponsive to beta blocker diuretic treatment
291. Angiotensin-converting enzyme inhibition, catecholamines and hemodynamics in essential hypertension
292. Efficacy of low dose captopril given twice daily to patients with essential hypertension uncontrolled by a beta blocker plus thiazide diuretic
293. Reversal of left ventricular hypertrophy with captopril: heterogeneity of response among hypertensive patients
294. Transient renal dysfunction during initial inhibition of converting enzyme in congestive heart failure
295. The influence of food intake on pharmacodynamics and plasma concentration of captopril
296. Long-term captopril therapy in congestive heart failure: serial hemodynamic and echocardiographic changes
297. Effects of captopril on survival in patients with heart failure
298. Hemodynamic effects of captopril in pulmonary hypertension of colagen vascular disease
299. Effects of captopril on peripheral hemodynamics in severe congestive heart failure
300. Serum zinc is unaffected by effective captopril treatment of hypertension
301. Treatment of neonatal hypertension with captopril
302. Renal failure due to enalapril and captopril in bilateral renal artery stenosis: greater awareness needed
303. A long term follow up of patients with essential hypertension treated with captopril
304. Pharmacokinetics of captopril and its effects on blood pressure during acute and chronic administration and in relation to food intake
305. Side effects and metabolic effects of converting enzyme inhibitors
306. Role of endogenous angiotensin II and prostaglandins in the -antihypertensive mechanism of angiotensin converting enzyme inhibitor in hypertension
307. Combined captopril and hydrochlorothiazide therapy in severe hypertension: long-term haemodynamic changes at rest and during exercise
308. Blood concentrations and urinary excretion of captopril (SQ 14,225) in patients with chronic renal failure
309. Converting-enzyme inhibition for severe chronic heart failure: views from a skeptic
310. Does vasodilator therapy alter prognosis in patients with severe chronic heart failure: comparative effects of hydralazine and captopril and survival in 175 patients treated over a 6-year period
311. Comparative effects of two converting-enzyme inhibitors on renal function in patients with severe chronic heart failure: a prospective randomized clinical trial
312. Influence of renal function on the hemodynamic and clinical responses to long term captopril therapy in severe chronic heart failure
313. Functional renal insufficiency during long term therapy with captopril and enalapril in severe chronic heart failure
314. Comparison of captopril and enalapril in patients with severe chronic heart failure
315. Contrasting hemodynamic responses in severe heart failure: comparison of captopril and other vasodilator drugs
316. Efficacy of captopril in lowrenin congestive heart failure: importance of sustained reactive hyperreninemia in distinguishing responders from nonresponders
317. Relation between serum sodium concentration and the haemodynamic and clinical responses to converting enzyme inhibition with captopril in severe heart failure
318. Comparative hemodynamic and clinical effects of long-term treatment with prazosin and captopril for severe chronic congestive heart failure secondary to coronary artery disease or idiopathic dilated cardiomyopathy
319. Comparative immediate hemodynamic and hormonal effects of amrinone and captopril in patients with severe chronic heart failure
320. Comparative effects of captopril and isosorbide dinitrate on pulmonary arteriolar resistance and right ventricular function in patients with severe left ventricular failure: results of a randomized crossover study
321. Usefulness of plasma renin activity in predicting haemodynamic and clinical responses and survival during long term converting enzyme inhibition in severe chronic heart failure
322. Quantitative differences in the hemodynamic effects of captopril and nitroprusside in severe chronic heart failure
323. Enalapril, captopril and blood glucose. Correspondence
324. Effect of captopril on the cerebral circulation in chronic heart failure
325. Simplified determination of captopril in plasma by high-performance liquid chromatography
326. Determination of captopril by an improved high-performance liquid chromatography-electrochemical assay
327. Synergistic effect of minoxidil and captopril in patients with refractory hypertension
328. Effects of captopril on renal function in hypertensive patients
329. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction
330. Comparison of antihypertensive and hormonal effects of captopril and propranolol at rest and during exercise
331. Combined nifedipine and captopril treatment in moderately severe primary hypertension
332. Captopril elimination during hemodialysis and in chronic renal failure
333. The use of captopril in severe treatment resistant hypertensive patients
334. The effect of captopril (SQ 14,225) upon mother and fetus in the chronically cannulated ewe and in the pregnant rabbit
335. Comparison of nifedepine and captopril as third-line agents in hypertensive patients uncontrolled with a beta blocker and diuretic therapy
336. The effect of captopril on renal, coronary, and systemic hemodynamics in patients with severe congestive heart failure
337. A double-blind comparison of lisinopril with captopril in patients with symptomatic congestive heart failure
338. Life quality in patients under hypotensive treatment
339. Intravenous captopril treatment in patients with severe cardiac failure
340. Captopril-associated cholestatic jaundice
341. Changes in cerebral blood flow in patients with severe congestive cardiac failure before and after captopril treatment
342. Converting enzyme inhibition in mild and moderate essential hypertension
343. Role of angiotensin-converting enzyme inhibitors in early antihypertensive treatment in non-insulin dependent diabetes mellitus
344. Once daily administration of captopril and hypotensive effect
345. Further experience with once-daily captopril monotherapy in essential hypertension
346. Kinetics of inhibition of angiotensin converting enzyme by captopril and by enalapril diacid
347. Chronic angiotensin converting enzyme inhibition as an alternative to native kidneys removal in post-transplant hypertension
348. Sustained haemodynamic and clinical effects of captopril in long term treatment of severe chronic congestive heart failure
349. Captopril as treatment for patients with pulmonary hypertension
350. Effects of captopril on pulmonary haemodynamics
351. Double-blind comparison of captopril alone against frusemide plus amiloride in mild heart failure
352. Captopril: pharmacokinetics, antihypertensive and biological effects in hypertensive patients
353. Inappropriately high secretion of antidiuretic hormone in patients with severe heart failure before and after captopril treatment
354. Effect of long-term inhibition of converting enzyme on carbohydrate metabolism in non-insulin dependent diabetic patients with essential hypertension
355. Placebo controlled comparison of captopril, atenolol, labetolol and pindolol in hypertension complicated by intermittent claudication
356. Captopril: an update review of its pharmacological properties and therapeutic efficacy in congestive heart failure
357. Utilidad de los inhibidores de la enzima conversiva de la angiotensina en el tratamiento de la nefrapatía diabética
358. Captopril elimination in chronic renal failure
359. Resolution of captopril-induced rash after substitution of enalapril
360. Alterations in left ventricular function and coronary hemodynamics with captopril, hydralazine and prazosin in chronic ischemic heart failure: a comparative study
361. Enalapril versus captopril: a double-blind multicentre comparison in essential hypertension
362. Use of angiotensin I to II converting enzyme inhibitor SP 14225 (Captopril) in moderate essential hypertension
363. Fatal bone-marrow suppression associated with captopril
364. Treatment of renal hypertension in children by captopril
365. Captopril and nifedipine interactions in the treatment of essential hypertensions: a crossover study
366. Influence of food on acute and chronic effects of captopril in essential hypertensive patients
367. Differential effects of selective and non-selective prostaglandin-synthesis inhibition on the pharmacological responses to captopril patients with essential hypertension
368. The influence of indomethacin on pharmacological actions of captopril in renovascular patients
369. Peripheral neuropathy due to captopril
370. Effects of captopril on blood pressure and renin-angiotensin-aldosterone system in hypertensive subjects after inhibition of renal vasodilative system
371. Long term captopril treatment in moderate to severe hypertension
372. Relationship between vasopressin and the renin-angiotensin-aldosterone system in essential hypertension: effect of converting enzyme inhibitor on plasma vasopressin
373. Clinical experience with captopril in hypertension
374. The ‘M’ value, an index of blood sugar control in diabetes
375. Once daily treatment of essential hypertension with captopril
376. Results of a 5-year study of captopril in patients with severe therapy-resistant hypertension (translation)
377. Serum potassium concentrations after initiation of captopril therapy
378. Captopril combined with minoxidil, beta blocker and furosemide in the treatment of refractory hypertension
379. Hemodynamic effects of captopril in chronic heart failure: efficacy of low-dose treatment and comparison with prazosin
380. Prazosin and captopril in chronic heart failure: comparison of acute haemodynamic and hormonal effects
381. Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction
382. Plasma free captopril concentrations during short and long term treatment with oral captopril for heart failure
383. Regression of cardiac hypertrophy after antihypertensive therapy with nifedipine and captopril
384. Effects of captopril, an angiotensin-converting enzyme inhibitor, in normotensive sodium-replete volunteers
385. The influence of captopril, the nitrates and propranolol on apparent liver blood flow
386. Determination of captopril in human blood by high-performance liquid chromatography with electrochemical detection
387. Captopril-associated granulocytopenia in hypertension after renal transplantation
388. Angiotensin converting enzyme inhibitors and the therapy of hypertension. Cited in Omae et al
389. Glucose tolerance during chronic captopril therapy in patients with essential hypertension
390. Angiotensin converting enzyme inhibitor treatment of hypertension in infancy and childhood
391. 2 metabolite levels, renin-angiotensin system and catecholamines versus acute haemodynamic response to captopril in chronic congestive heart failure
392. Acute hypotensive effect of captopril in man modified by prostaglandin synthesis inhibition
393. Effects of acute and chronic angiotensin-converting enzyme inhibition on large arteries in human hypertension
394. Action of vasodilating drugs on small and large arteries of hypertensive patients
395. Antihypertensive drug therapy with captopril in children and adolescents
396. Captopril and nifedipine in combination for moderate to severe essential hypertension
397. Renal handling of captopril: effect of probenecid
398. Effect of food on the bioavailability of captopril in healthy subjects
399. Zinc deficiency during captopril treatment
400. Cutaneous reactions to captopril: predictive value of skin tests
401. Effect of captopril on plasma prostacyclin concentration in essential hypertensive patients
402. Mechanism of captopril-induced agranulocytosis
403. Doubleblind comparison between propranolol and bendroflumethiazide in captopril-treated resistant hypertensive patients
404. Haemodynamic and hormonal interactions between captopril and nifedipine
405. Reversible captopril-associated bone marrow aplasia
406. Long term efficacy of angiotensin-converting-enzyme inhibition with captopril in mild to moderate essential hypertension
407. Effects of converting enzyme inhibition on blood pressure, plasma renin activity and plasma aldosterone in hypertensive diabetics compared to patients with essential hypertension
408. Angiotensin-converting enzyme inhibition and prostaglandins
409. Endocrine profile in the long-term phase of converting enzyme inhibition
410. Effect of captopril on heavy proteinuria in azotemic patients
411. Acute effects of oral captopril on hemodynamics in patients with cor pulmonale
412. Haemodynamic and volume changes associated with captopril
413. Regulation of renal haemodynamics and glomerular filtration in patients with renovascular hypertension during converting enzyme inhibition with captopril
414. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure
415. Reduction of plasma and urinary vasopressin during treatment of severe hypertension by captopril
416. A parallel study of enalapril and captopril and 1 year of experience with enalapril treatment in moderate-to-severe essential hypertension
417. Low dose captopril titration in patients with moderate to severe hypertension treated with diuretics
418. Effect of captopril on renal haemodynamics and the renin-angiotensinaldosterone and osmoregulatory systems in essential hypertension
419. Captopril in the treatment of scleroderma renal crisis
420. 2-adrenoceptor mediated vasoconstriction in vivo by captopril and MK-421
421. Enalapril: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure
422. Acute and long-term effects of captopril on exercise cardiac performance and exercise capacity in congestive heart failure
423. Effect of angiotensin-converting enzyme inhibitor therapy on proteinuria in children with renal disease
424. Combined treatment with minoxidil and captopril in refractory hypertension
425. A radioimmunoassay for total captopril in human serum or plasma samples
426. Low dose captopril in mild to moderate geriatric hypertension
427. Effects of captopril on systemic and renal haemodynamics in patients with diabetic nephropathy and renal insufficiency
428. The effect of captopril and propranolol on the responses to posture and isometric exercise in patients with essential hypertension
429. Radioimmunoassay of blood bradykinin: purification of blood extracts to prevent cross-reaction with endogenous kininogen
430. Captopril in hypertension after renal transplantation
431. Cardiovascular effects and regional blood flow distribution associated with angiotensin converting enzyme inhibition (captopril) in essential hypertension
432. Captopril: evaluation of low doses, twicedaily doses and the addition of diuretic for the treatment of mild to moderate hypertension
433. Racial differences in response to low-dose captopril are abolished by the addition of hydrochlorothiazide
434. Low dose captopril for the treatment of mild to moderate hypertension
435. Time course of antihypertensive effect of low-dose captopril in mild to moderate hypertension
436. Double-blind comparison of captopril and enalapril in mild to moderate hypertension
437. 2-metabolites after angiotensin converting enzyme inhibition in hypertensive patients
438. Captopril withdrawal after chronic therapy
439. Low-dose captopril: its use in mild to moderate hypertension unresponsive to diuretic treatment
440. Discrepancy between antihypertensive effect and angiotensin converting enzyme inhibition by captopril
441. Deterioration of renal function in hypertensive patients with scleroderma despite blood pressure normalisation with captopril
442. Acute and chronic effects of captopril therapy in patients with refractory heart failure
443. Reversible severe thrombocytopaenia associated with captopril
444. Captopril in mild and severe hypertension
445. Autonomic and baroreflex function after captopril in hypertension
446. Captopril-induced agranulocytosis in systemic sclerosis
447. Safety issues during antihypertensive treatment with angiotensin converting enzyme inhibitors
448. Comparison of captopril and hydrochlorothiazide alone and in combination in mild to moderate essential hypertension
449. Role of sympathetic nervous system activity in the blood pressure response to long-term captopril therapy in severely hypertensive patients
450. Hemodynamic effects of captopril in essential hypertension, renovascular hypertension and cardiac failure: correlations with short- and long-term effects on plasma renin
451. Effects of captopril in acute and chronic heart failure: correlations with plasma levels of noradrenaline, renin, and aldosterone
452. Split renal function after captopril in unilateral renal artery stenosis
453. Variable response to oral angiotensin-converting-enzyme blockade in hypertensive scleroderma patients
454. ‘First dose’ effect of captopril
455. The effect of a meal, at various times relative to drug administration, on the bioavailability of captopril
456. 3H] captopril
457. Captopril may adversely affect renal function in hypertensive diabetics without established nephropathy
458. Comparative double-blind study of ramipril and captopril in mild to moderate essential hypertension
459. Acute haemodynamic and hormonal effects of captopril are diminished by indomethacin
460. Involvement of prostaglandins in the actions of captopril
461. 14C]-captopril in the blood of rats, dogs and humans
462. A single-blind, randomised cross-over study of angiotensin-converting enzyme inhibitor and triamterene and hydrochlorothiazide in the treatment of mild to moderate hypertension in the elderly
463. Clinical course of patients with scleroderma renal crisis treated with captopril
464. Actions of angiotensin on adrenergic nerve endings
465. Zinc metabolism during captopril treatment
466. Efficacy of an oral angiotensin-converting enzyme inhibitor (captopril) in severe hypertension